← Eichor
Study identifier: NCT06265038 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Confirmatory Investigation to Evaluate the Performance and Safety of ReSpace TiCell Cage Implants in TLIF

Condition: Degenerative Instability · Spondylolisthesis · Post-discectomy Syndrome  ·  Sponsor: Sanatmetal Orthopaedic and Traumatologic Equipment Manufacturer Ltd.

PhaseNA
Planned participants99
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

The primary objective of this study is to confirm superiority for the efficacy of the ReSpace Ticell Cage implants in Transforaminal Lumbar Interbody Fusion compared to state-of-the-art. The secondary objective of the study is to evaluate further efficacy and safety of the ReSpace Ticell Cage implants in Transforaminal Lumbar Interbody Fusion with the following secondary efficacy and safety objectives: * To evaluate if implantation causes significant reduction in patient's back, hip/buttock, and leg pain. * To evaluate if implantation causes significant increase quality of life of the patients. * To evaluate if using the device can be considered as safe overall.

This description comes directly from the study's public registry record.

Talk to the study team

Bálint Kozma  ·  +3630 6861784  ·  bkozma@sanatmetal.hu

Always discuss trial participation with your own doctor first.

Locations (1)

National Center for Spinal DisordersBudapest, Pest County, HungaryRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06265038